[PRNewswire] Jemincare group has completed the Phase I clinical trial of its
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
anti-SARS-CoV-2 neutralizing antibody JMB2002
(SHANGHAI, Sept. 14, 2021 PRNewswire=연합뉴스) Recently, Jemincare group has declared that it has completed phase I clinical trial of self-developed novel coronavirus specific neutralizing antibody (Project code: JMB2002).
The clinical trial of JMB2002 was stated in January 2021. A single-center, randomized, double-blind, placebo-controlled, single-dose escalation phase I trial was designed to evaluate JMB2002's tolerability, safety, pharmacokinetic characteristics and immunogenicity in healthy subjects. In this study, 40 subjects were enrolled in 4 dose groups from low to high. All 40 participants have completed the entire trial. The results have shown that only one subject underwent grade 2 adverse events (TEAE) related to the study drug. The other TEAEs were all in grade 1, and all TEAEs were in remission or completely recovered. None of the subjects had any serious adverse events (SAE) related to the study drug.
In terms of pharmacokinetics, after a single intravenous infusion of JMB2002, the Cmax and AUC elevated with the increasing of dosage, and the Tmax decreased with the increasing of dosage. There were no significant changes in the parameters like T1/2, Vz, CLz, λz and MRT among different dose groups. In terms of drug immunogenicity, anti-drug antibody was detected in only 1 subject before and after administration of the drug, while no anti-drug antibodies were detected in all the other subjects.
According to the results of phase 1 clinical study, JMB2002 is worthy of further exploration of clinical efficacy study in patients with COVID-19 virus infection, in order to contribute to the treatment of COVID-19 in the world.
To deal with the challenge of viral escape, Jemincare is continuing to develop new broad-spectrum neutralizing antibodies against SARS-CoV-2. To date, R & D team has obtained second generation neutralizing antibodies with better neutralizing activity against all variants of concern including the Alpha, Beta, Gamma and Delta variants in pseudo-virus neutralizing assay. Furthermore, these antibodies could be developed as a cocktail therapy that provide more options for the control of global COVID-19 pandemic and prevent the immune-escape of SARS-CoV-2 virus, as they recognize different epitope bins of SARS-CoV-2 S1.
As early as the outbreak of the COVID-19 pandemic, Jemincare R & D team has efficiently isolated the neutralizing antibody JMB2002 targeting SARS-CoV-2 RBD from a naive human antibody library containing over 1010 clones. Based on Phage-to-Yeast (PtY) antibody discovery platform, a novel competitive FACS approach was developed during the high-throughput screening step. That is, the library was incubated with SARS-CoV-2 S1 RBD and hACE2 protein which led to the maximum simulation of hACE2 by the antibody. The fully human anti-SARS-CoV-2 neutralizing antibody was obtained in only 19 days using PtY platform.
PtY antibody discovery platform has the advantages of high-throughput and real time visualized multidimensional screening. It rapidly and precisely screened out antibody candidates recognizing desired epitopes against targets, that dramatically shortened time in early discovery stage. Based on PtY and other antibody discovery platforms, biologics institute of Jemincare group has built up a portfolio of more than 10 clinical and pre-clinical stage antibody projects focusing on kidney, tumor, asthma and anti-infectious disease areas to benefit thousands of patients in the near future.
Source: Jemincare
[편집자 주] 본고는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았음을 밝혀 드립니다.
(끝)
출처 : PRNewswire 보도자료
Copyright © 연합뉴스 보도자료. 무단전재 및 재배포 금지.
- 체코 당국, EDF·웨스팅하우스 '韓원전 계약' 진정 기각(종합2보) | 연합뉴스
- 野 "불법 공천개입" 용산 "공천지시한 적 없다"…11월 정국 격랑 | 연합뉴스
- 북한, 美대선 앞두고 ICBM 도발…정부, 새 대북 독자제재 발표 | 연합뉴스
- 젤렌스키 "북한군과 며칠내 교전 예상…한국서 방공망 필요" | 연합뉴스
- 최대 경합주 펜실베이니아, 조사기관 따라 우위 바뀌며 '대혼전' | 연합뉴스
- 檢, '대북송금' 이화영에 2심도 징역 15년 구형…내달 29일 선고(종합2보) | 연합뉴스
- "하늘나라서 행복해야 해"…7세 초등생 친구·주민들 추모 발길(종합) | 연합뉴스
- 유럽 심장서 2천400억 최대 수출실적…세계한인경제인대회 성료 | 연합뉴스
- 태풍 '콩레이' 비바람 안고 한반도로…정부, 피해 최소화 점검 | 연합뉴스
- 고려아연에 칼빼든 금감원…"공개매수 중 유증, 부정거래 소지"(종합2보) | 연합뉴스